Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

Viatris launches $36.50-per-share cash tender offer to acquire Pacira BioSciences.

What the company is saying

Viatris Inc. is formally initiating a tender offer, through its subsidiary Peach Purchaser Sub Inc., to acquire all outstanding shares of Pacira BioSciences, Inc. at $36.50 per share in cash, net of applicable withholding taxes and without interest. The company frames this as a definitive step under an Agreement and Plan of Merger signed on October 8, 2026, emphasizing that the merger will proceed without requiring a Pacira stockholder vote due to Section 251(h) of Delaware law. The announcement highlights the unanimous recommendation from Pacira’s board, disclosed via a Schedule 14D-9 filing with the SEC on October 30, 2026, urging shareholders to accept the offer. Viatris stresses that the offer is not subject to a financing condition, underlining transaction certainty. The tone is procedural and neutral, focusing on transaction mechanics, regulatory steps, and deadlines, with no promotional language or forward-looking synergy claims.

What the data suggests

The offer price is $36.50 per Pacira share, payable in cash, with the par value of Pacira common stock stated as $0.001 per share. The offer period expires one minute after 11:59 p.m. Eastern Time on November 16, 2026, unless extended. The Minimum Condition requires that more than 50% of Pacira’s outstanding shares be validly tendered and not withdrawn for the offer to proceed. The merger consideration matches the tender offer price, ensuring all remaining shares are cashed out at $36.50 if the merger closes. Withdrawal rights for tendered shares extend until the offer expires, and if not accepted for payment, can be exercised again after December 29, 2026. The process is not subject to a financing condition, and regulatory clearance under the Hart-Scott-Rodino Act is required. No financial performance data, operational results, or strategic rationale are disclosed. The facts are complete for understanding the transaction’s legal and procedural framework, but do not address the financial impact or rationale for either company.

Analysis

The announcement is a formal, procedural disclosure of a tender offer and planned merger, with clear terms, deadlines, and conditions. The language is factual and avoids promotional or exaggerated claims, focusing on the mechanics of the transaction rather than projecting future synergies, growth, or financial benefits. While some statements are forward-looking (e.g., the merger's completion and share conversion), these are standard in such transactions and are not presented as guaranteed outcomes or hyped achievements. There is no discussion of strategic rationale, expected returns, or operational impact, and no financial or profitability metrics are disclosed. The capital outlay is significant (cash offer for all shares), but the process is governed by a signed agreement and is not subject to a financing condition, reducing execution risk. Overall, the narrative is proportionate to the evidence and does not inflate the signal.

Risk flags

• ●Regulatory approval under the Hart-Scott-Rodino Antitrust Improvements Act is required before the offer can close; any delay or issue in obtaining clearance could postpone or jeopardize the transaction.
• ●The offer is contingent on the Minimum Condition—more than 50% of Pacira shares must be validly tendered and not withdrawn. If insufficient shares are tendered, the transaction will not proceed, exposing the deal to shareholder acceptance risk.
• ●There is no disclosed strategic or financial rationale for the acquisition in this announcement, leaving investors without insight into potential synergies, integration risks, or the impact on Viatris’s financials.
• ●The absence of a financing condition reduces risk, but the lack of disclosed funding details means investors cannot assess the impact on Viatris’s balance sheet or liquidity post-transaction.

Bottom line

Viatris’s $36.50-per-share cash tender offer for Pacira BioSciences is now formally underway, with a near-term expiration date of November 16, 2026. The process is governed by a signed merger agreement and does not require Pacira shareholder approval, but hinges on regulatory clearance and a minimum tender threshold. The announcement is thorough on procedural details but omits any discussion of strategic fit, expected synergies, or financial impact, leaving investors without a basis to assess the deal’s value creation potential. The lack of a financing condition suggests Viatris has the means to complete the transaction, but the absence of funding specifics or pro forma financials is a gap. Investors should focus on whether the minimum tender and regulatory conditions are met by the deadline, as these are the immediate catalysts. The most important takeaway is that while the transaction mechanics are clear and the timeline is short, the investment rationale remains unaddressed in this disclosure.

Announcement summary

(NASDAQ:VTRS) Viatris Inc. announced that its wholly owned subsidiary, Peach Purchaser Sub Inc., has commenced a tender offer to purchase all issued and outstanding shares of common stock, par value $0.001 per share, of Pacira BioSciences, Inc. (NASDAQ:PCRX) for $36.50 per share in cash, net of applicable withholding taxes and without interest. The offer is made pursuant to the Agreement and Plan of Merger dated October 8, 2026, among Viatris, Purchaser, and Pacira. Following the consummation of the offer, Purchaser will be merged with and into Pacira, with Pacira continuing as the surviving corporation and becoming a wholly owned subsidiary of Viatris. Each share issued and outstanding immediately prior to the effective time of the merger will be converted into the right to receive $36.50 per share in cash, net of applicable withholding taxes and without interest. The merger will be governed by Section 251(h) of the Delaware General Corporation Law and does not require a vote of Pacira's stockholders. Purchaser may not provide any subsequent offering period for the offer without the prior written consent of Pacira. Pacira's board of directors has published a Solicitation/Recommendation Statement on Schedule 14D-9 and filed it with the SEC on October 30, 2026, which includes the unanimous recommendation that Pacira's stockholders accept the offer and tender their shares. The offer and withdrawal rights will expire one minute following 11:59 p.m. Eastern Time on November 16, 2026, unless extended or earlier terminated. Shares tendered may be withdrawn at any time prior to the expiration date and, if not yet accepted for payment, may also be withdrawn at any time after December 29, 2026. Purchaser will promptly accept for payment and pay for all shares validly tendered and not validly withdrawn as soon as practicable after the offer acceptance time. The obligation to pay for shares is subject to certain conditions, including the Minimum Condition, expiration or termination of the Hart-Scott-Rodino waiting period, and the absence of any legal restraint prohibiting the offer or merger. The Minimum Condition requires that, prior to the expiration date, there have been validly tendered (and not validly withdrawn) a number of shares that, together with shares owned by Purchaser and its affiliates, represents at least one share more than 50% of the total number of shares issued and outstanding at the time of expiration, excluding shares tendered by guaranteed delivery procedures not yet received by the depository. The offer is not subject to a financing condition. Pacira has provided Purchaser with its stockholder list and other information for the purpose of disseminating the offer. The offer documents are available at https://www.shareholdermaterials.com/pcrx2026/.

Disagree with this article?